Abstract
Background
ADCY5 mutation is a clinical condition that has been described in limited numbers in the literature, causing hyperkinetic movement disorder, and may be sporadic or familial.
Patient description
This report looks at the involuntary movements that started early in life in a 5-year-old girl.
Results
Patient’s electroensephalogram and cranial magnetic resonance imaging were normal. Metabolic scans were normal. ADCY5 mutation was found in whole exome sequencing of the patient who did not have a similar family history.
Conclusion
Some features such as the worsening of involuntary movements after sleep and the presence of hypotonia in our patient suggested this mutation. Our patient is resistant to more than one drug. With this report, we aimed to pave the way for better understanding of the gene and the discovery of different treatment options.
This is a preview of subscription content, log in via an institution to check access.
References
Chen DH, Méneret A, Friedman JR et al (2015) ADCY5-related dyskinesia: broader spectrum and genotype− phenotype correlations. Neurology 85:2026–2035
Vijiaratnam N, Bhatia KP, Lang AE, Raskind WH, Espay AJ (2019) ADCY5–related dyskinesia: ımproving clinical detection of an evolving disorder. Mov Disord 6(7):512–520
Chang FC, Westenberger A, Dale RC et al (2016) Phenotypic insights into ADCY5-associated disease. Mov Disord 31:1033–1040
Carapito R, Paul N, Untrau M et al (2015) A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia. Mov Disord 30:423–427
Matsuoka I, Suzuki Y, Defer N, Nakanishi H, Hanoune J (1997) Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain. J Neurochem 68:498–506
Roberts DCS, Koob GF, Klonoff P, Fibiger HC (1980) Extinction and recovery of cocaine selfadministration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmac Biochem Behav 12(5):781–787
Méneret A, Mohammad SS, Cif L, Doummar D et al (2022) Efficacy of caffeine in ADCY5-related dyskinesia: a retrospective study. Mov Disord 37(6):1294–1298
Tübing J, Bohnenpoll J, Spiegler J, Gillessen-Kaesbach G, Bäumer T, Max C et al (2018) Methylphenidate can improve chorea in NKX2.1 and ADCY5 mutation-positive patients-a report two children. Mov Disord Clin Pract 5(3):343–345
Dy ME, Chang FCF, Jesus SD, Anselm I, Mahant N, Zeilman P et al (2016) Treatment of ADCY5-associated dystonia, chorea, and hyperkinetic disorders with deep brain stimulation: a multicenter case series. J Child Neurol 31(8):1027–1035
Doyle TB, Hayes MP, Chen DH, Raskind WH, Watts VJ (2019) Functional characterization of AC5 gain-of-function variants: impact on the molecular basis of ADCY5-related dyskinesia. Biochem Pharmacol 163:169–177
Ferrini A, Steel D, Barwick K, Kurian M (2021) An update on the phenotype, genotype and neurobiology of ADCY5-related disease. Mov Dis 36(5):1104–1114
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and consent to participate
None.
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
The manuscript has been read and approved by all authors, Didem Tezen, Ayşegül Gündüz, Meral Erdemir Kızıltan, Cengiz Yalçınkaya, Güneş Kızıltan and the requirements of authorship have been met. Informed consent form of patient is approved by patients father legal heir of her.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tezen, D., Gunduz, A., Erdemir Kiziltan, M. et al. ADCY5 gene mutation: a case report. Neurol Sci 43, 6947–6950 (2022). https://doi.org/10.1007/s10072-022-06394-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-022-06394-0